Table 2.
The number of pXDDIs, for which the CP recommended drug discontinuation
| pXDDIs | N prior | N after | pXDDIs | N prior | N after |
| Amiodarone-torsemide | 1 | 0 | ipratropium / fenoterol-tiotropium | 3 | 2 |
| Amiodarone-clozapine | 1 | 0 | quetiapine-amiodarone | 1 | 0 |
| Amiodarone-warfarin | 1 | 0 | quetiapine -domperidone | 2 | 1 |
| Etoricoxib-meloxicam | 1 | 0 | quetiapine -escitalopram | 7 | 3 |
| Haloperidol-sulpiride | 2 | 1 | quetiapine-metoclopramide | 3 | 2 |
| Haloperidol-metoclopramide | 1 | 0 | quetiapine-sulpiride | 2 | 1 |
| Cholecalciferol-calcitriol | 3 | 0 | metoclopramide-trimetazidine | 2 | 1 |
| Ipratropium/fenoterol-Olanzapine | 2 | 1 | sulpiride-risperidone | 1 | 0 |
| Not accepted pXDDIs | N prior | N after | pXDDIs | N prior | N after |
| Amisulpride-sulpiride | 1 | 1 | quetiapine-budenoside / formoterol | 1 | 1 |
| Desloratadine-mirtazapine | 1 | 1 | quetiapine-domperidone | 2 | 1 |
| Escitalopram-sotalol | 1 | 1 | quetiapine-escitalopram | 7 | 3 |
| Haloperidol-sulpiride | 2 | 1 | quetiapine-haloperidol | 3 | 3 |
| Haloperidol- ipratropium/phenoterol | 1 | 1 | quetiapine-metoclopramide | 3 | 2 |
| Haloperidol ipratropium/phenoterol- | 1 | 1 | quetiapine-sulpiride | 2 | 1 |
| Olanzapine- ipratropium/phenoterol | 2 | 1 | quetiapine-trazodone | 1 | 1 |
| Quetiapine-tiotropium | 1 | 1 | quetiapine-tiotropium | 1 | 1 |
| Carbamazepine-clozapine | 3 | 2 | metoclopramide-trimetazidine | 2 | 1 |
| Carvedilol- budenoside/formoterol | 2 | 2 | olanzapine-thyrotropium | 1 | 1 |
| Quetiapine- ipratropium/phenoterol | 1 | 1 | sulpiride-trimetazidine | 1 | 1 |